INDIGO Home University of Illinois at Urbana-Champaign logo uic building uic pavilion uic student center

Resistance to TRAIL-induced apoptosis: role of IG20 splice variants

Show simple item record

Bookmark or cite this item:

Files in this item

File Description Format
PDF TRAIL-IG20-CCR.pdf (201KB) (no description provided) PDF
Title: Resistance to TRAIL-induced apoptosis: role of IG20 splice variants
Alternative Title: Role of IG20 splice variants in TRAIL resistance
Author(s): Prabhakar, Bellur S.; Mulherkar, Nirupama; Prasad, Kanteti V.
Abstract: Tumor necrosis factor receptor–related apoptosis-inducing ligand (TRAIL) can induce apoptosis primarily in cancer cells with little or no effect on normal cells; therefore, it has the potential for use in cancer therapy. TRAIL binding to death receptors DR4 and DR5 triggers the death-inducing signal complex formation and activation of procaspase-8, which in turn activates caspase-3, leading to cell death. Like FasL, TRAIL can trigger type 1 (caspase-8 caspase-3) or type 2 (caspase-8 Bid cleavage capsase-9 caspase-3) apoptotic pathways depending on the cell type. Some cancers are resistant to TRAIL treatment because most molecules in the TRAIL signaling pathway, including FLIPs and IAPs, can contribute to resistance. In addition, we have identified an essential role for splice variants of the IG20 gene in TRAIL resistance.
Issue Date: 2008-01
Publisher: American Association for Cancer Research
Citation Info: Prabhakar BS, Mulherkar N, Prasad KV. Role of IG20 splice variants in TRAIL resistance. Clin Cancer Res. 2008 Jan 15;14(2):347-51.
Type: Article
Description: Postprint version of article may differ from published version
ISSN: 1078-0432
Date Available in INDIGO: 2009-08-08

This item appears in the following Collection(s)

Show simple item record


Country Code Views
United States of America 333
China 163
Russian Federation 19
Ukraine 17
Germany 11


My Account


Access Key